Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

METiS Acquires Rights to Pan-RAF Inhibitor in $482 Million Agreement

publication date: Sep 15, 2022

METiS Therapeutics, a Boston-Shanghai AI company, in-licensed global rights to a pan-RAF inhibitor program from Korea’s Voronoi in a deal worth up to $482 million. METiS will pay only $1.7 million upfront, with provision for $480.5 million in milestone payments, plus royalties. In December 2021, METiS completed a $86 million Series A funding, exclusively from China investors. In May, the company joined the Shanghai Roche Accelerator, the first AI drug discovery company at the Accelerator. METiS will apply its AI and machine learning platforms to develop the Voronoi pan-RAF inhibitor. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital